Analyze the incidence of TET2 gene mutations and Validation of the prognostic potential of TET2 mutations and MPLA screening 2 years [clinicaltrials_resource:f19bbfb7a9ff754fc2c3af40650cb7e2]
Analyze the incidence of TET2 gene mutations in a series of MDS patients and describe the clinical status of patients carrying mutations
Validation of the prognostic potential of TET2 mutations and MPLA screening on:
Response rate to treatment with Epo, Lenalidomide and Azacitidine
Progression Free Survival (PFS )
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Analyze the incidence of TET2 gene mutations and Validation of the prognostic potential of TET2 mutations and MPLA screening 2 years [clinicaltrials_resource:f19bbfb7a9ff754fc2c3af40650cb7e2]
Analyze the incidence of TET2 gene mutations in a series of MDS patients and describe the clinical status of patients carrying mutations
Validation of the prognostic potential of TET2 mutations and MPLA screening on:
Response rate to treatment with Epo, Lenalidomide and Azacitidine
Progression Free Survival (PFS )
Bio2RDF identifier
f19bbfb7a9ff754fc2c3af40650cb7e2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:f19bbfb7a9ff754fc2c3af40650cb7e2
measure [clinicaltrials_vocabulary:measure]
Analyze the incidence of TET2 ...... 2 mutations and MPLA screening
time frame [clinicaltrials_vocabulary:time-frame]
description
Analyze the incidence of TET2 ...... ogression Free Survival (PFS )
identifier
clinicaltrials_resource:f19bbfb7a9ff754fc2c3af40650cb7e2
title
Analyze the incidence of TET2 ...... ons and MPLA screening 2 years
@en
type
label
Analyze the incidence of TET2 ...... bbfb7a9ff754fc2c3af40650cb7e2]
@en